CTCL
ALCANZA
The ALCANZA trial was a Phase 3 investigation examining BV in C-ALCL and MF patients. It aimed to evaluate overall survival, progression free survival with the therapy, as well as quality of life improvements compared to the physician’s choice therapy.
The trial included 128 patients who were randomized to either receive the BV treatment (64 patients) or the physician’s choice treatment (64 patients).
Results
At a median follow up period of 45.9 months, the following results were documented.
- Long-term safety and efficacy was 54.7% for those given BV
- Long-term safety and efficacy was 12.5% for those given the physician’s therapeutic choice
- The complete response rate for the BV group was 17.2%
- The complete response rate was 1.6% for the physician’s choice group
- BV did not improve overall survival (3 year overall survival rate was 64.4%)
- The physician’s choice group had a 3 year overall survival rate of 61.9%
- Median progression free survival was 16.7 months for the BV group
- Median progression free survival was 3.5 months for the physician’s choice group
- Median time to receiving the next treatment was 14.2 months for the BV group
- Median time to receiving the next treatment was 5.6 months for the physician’s choice group
- 44 participants in the BV group developed peripheral neuropathy
- 18 patients in the BV group had a grade 1-2 ongoing event when the data was analyzed
Reference
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106. doi:10.1182/bloodadvances.2021004710
You can read more about this study and what its findings could mean for patients here.
